Debiopharm Announces Purchase of All Outstanding Shares of H3

Debiopharm S.A., the independent drug development company specializing in oncology, endocrinology and niche products, has announced that it has purchased all the outstanding shares of H3 Pharma from Montreal-based Societe Generale de Financement du Quebec (SGF). H3 Pharma is a drug development company that was created in Montreal in June 2001, as the result of an equal partnership between SGF and the Debio Group. Since then, H3 Pharma has undergone an additional recapitalisation and holds shares in a German biotech company specialising in human antibodies for cancer therapy.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19227220&full=1)